Biocon receives US FDA approval for Liraglutide Injection gSaxenda
Approval covers 18 mg/3 mL prefilled pens for chronic weight management in the United States
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Biocon
The next wave of growth will belong not to the fastest manufacturers but to the most innovative…
As India moves into 2026, industry experts state that the next phase of growth in pharmaceuticals will depend on strengthening…
Biocon launches liraglutide for diabetes and obesity in the Netherlands
The products are marketed as Diavorin and Vobexoryn through Pharmamedic B.V.
The R&D playbook for complex generics
Dr Rakesh Bhasin, Head R&D (Formulations), Biocon, gave a presentation on 'The R&D playbook for complex generics'. He…
Biocon unveils first US manufacturing facility in Cranbury, New Jersey
Biocon, an innovation-led global biopharmaceutical company has announced the inauguration of its first US manufacturing facility…
Panel Discussion Injectable therapies 2.0: Driving patient-friendly parenteral drug delivery
The eighth edition of the FDD Conclave organised by Express Pharma witnessed a very interesting panel discussion on Injectable…
ATMF report reveals that insulin remains out of reach for T1D patients in LMICs, children facing…
ATMF report recommends practical solutions whereby companies can bring about the fundamental shift that is required to scale up…
Biocon Biologics signs US settlement with Regeneron to Launch Yesafili Biosimilar by 2026
Settlement agreement allows Biocon Biologics to commercialise interchangeable aflibercept biosimilar Yesafili in the US; launch…
Biocon’s S&P Global ESG Score improves to 69 for 2024
Biocon’s subsidiary Biocon Biologics, which also participated independently in the assessment for the first time, reported an…
Innovation, partnerships and best practices: Priorities for biopharma in 2025
Industry experts highlight the progress made by the Indian biopharma sector, and suggest pathways to promote growth